Polycythemia Secondary to Renal Hemangioblastoma: A Case Report and Literature Review.

Secondary polycythemia is a paraneoplastic syndrome observed in tumors with excessive erythropoietin (EPO) production. Renal cell carcinoma (RCC) and cerebellar hemangioblastoma are the 2 most well-known tumors to induce secondary polycythemia. Hemangioblastomas occurring in the kidney are rare. In this work we present a case of renal hemangioblastoma that caused erythrocytosis in a 19-year-old man. We demonstrated intratumoural EPO production by immunohistochemistry, and conducted whole-exome sequencing to evaluate possible genetic alterations that reported to induce tumor-related polycythemia. In spite of an indolent clinical behavior, renal hemangioblastoma is difficult to differentiate from RCC not only clinically, but also histopathologically. Given that RCC is the most well-known renal tumor to induce erythrocytosis, the uncommon manifestation of polycythemia in renal hemangioblastoma, as shown in our case, can cause further diagnostic challenges. Renal hemangioblastoma should be listed in the differential diagnoses of renal tumors presenting with erythrocytosis, apart from the most common RCC.

[1]  J. Houldsworth,et al.  Primary hemangioblastoma of the kidney with molecular analyses by next generation sequencing: a case report and review of the literature , 2021, Diagnostic Pathology.

[2]  Lanjuan Li,et al.  A novel germline gain-of-function HIF2A mutation in hepatocellular carcinoma with polycythemia , 2020, Aging.

[3]  M. Mitterberger,et al.  Sporadic renal hemangioblastoma: A case report of a rare benign renal tumor , 2019, Clinical case reports.

[4]  M. Bisceglia,et al.  Extraneuraxial hemangioblastoma: A clinicopathologic study of 10 cases with molecular analysis of the VHL gene. , 2018, Pathology, research and practice.

[5]  M. Kaushal,et al.  Intracranial hemangioblastoma – A SEER-based analysis 2004–2013 , 2018, Oncotarget.

[6]  K. Pacak,et al.  A novel splicing site IRP1 somatic mutation in a patient with pheochromocytoma and JAK2V617F positive polycythemia vera: a case report , 2018, BMC Cancer.

[7]  Hongyang Wang,et al.  Erythrocytosis in hepatocellular carcinoma portends poor prognosis by respiratory dysfunction secondary to mitochondrial DNA mutations , 2017, Hepatology.

[8]  K. Cibulskis,et al.  Sporadic hemangioblastomas are characterized by cryptic VHL inactivation , 2014, Acta neuropathologica communications.

[9]  Liang Cheng,et al.  PAX8 expression in sporadic hemangioblastoma of the kidney supports a primary renal cell lineage: implications for differential diagnosis. , 2013, Human pathology.

[10]  Glenda C Gobe,et al.  Functional significance of erythropoietin in renal cell carcinoma , 2013, BMC Cancer.

[11]  Chung‐Chieh Wang,et al.  Sporadic Hemangioblastoma of the Kidney in a 29-Year-Old Man , 2012, International journal of surgical pathology.

[12]  R. Hoffman,et al.  Why does my patient have erythrocytosis? , 2012, Hematology/oncology clinics of North America.

[13]  H. Gröne,et al.  Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia , 2007, International journal of cancer.

[14]  U. Shankavaram,et al.  Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia , 2014, Journal of Molecular Medicine.